Zura Bio (NASDAQ:ZURA) Announces Earnings Results, Misses Estimates By $0.01 EPS

Zura Bio (NASDAQ:ZURA) posted its quarterly earnings results on Tuesday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01), Zacks reports.

Zura Bio Stock Up 1.1%

ZURA stock traded up $0.06 during mid-day trading on Tuesday, hitting $5.69. 422,453 shares of the company were exchanged, compared to its average volume of 825,798. Zura Bio has a 12-month low of $1.39 and a 12-month high of $7.44. The firm has a market capitalization of $539.87 million, a P/E ratio of -5.22 and a beta of -0.02. The business has a fifty day simple moving average of $4.84 and a 200-day simple moving average of $5.41.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on ZURA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a report on Monday, July 6th. William Blair assumed coverage on shares of Zura Bio in a research report on Wednesday, July 8th. They set an “outperform” rating on the stock. Wedbush reissued an “outperform” rating and issued a $15.00 price objective on shares of Zura Bio in a report on Wednesday, July 1st. Finally, Wall Street Zen raised shares of Zura Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Zura Bio has a consensus rating of “Moderate Buy” and an average target price of $10.75.

Hedge Funds Weigh In On Zura Bio

A number of hedge funds have recently made changes to their positions in ZURA. XTX Topco Ltd acquired a new stake in Zura Bio in the 4th quarter valued at approximately $348,000. Suvretta Capital Management LLC grew its stake in shares of Zura Bio by 1.7% in the fourth quarter. Suvretta Capital Management LLC now owns 5,567,001 shares of the company’s stock valued at $29,171,000 after buying an additional 94,110 shares in the last quarter. Quadrature Capital Ltd acquired a new stake in shares of Zura Bio in the fourth quarter valued at $192,000. Millennium Management LLC raised its holdings in shares of Zura Bio by 75.1% in the 4th quarter. Millennium Management LLC now owns 1,032,680 shares of the company’s stock valued at $5,411,000 after buying an additional 442,980 shares during the period. Finally, VR Adviser LLC raised its holdings in shares of Zura Bio by 15.4% in the 4th quarter. VR Adviser LLC now owns 5,345,115 shares of the company’s stock valued at $28,008,000 after buying an additional 713,899 shares during the period. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.